PROMISING EARLY SAFETY DATA8 Feb 2022 07:45
Repost
PROMISING EARLY SAFETY DATA
Toxicology results IMO is the deal maker?
I was just having a little browse through some resent RNSs and this kind of chilled me out!!!
Trading Statement 11th August 2020
OPERATIONAL HIGHLIGHTS
Selective TYK2/JAK1 Inhibitors in Autoimmune Diseases and Cancer
Sareum is continuing to advance its proprietary selective dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as potential once-daily, oral immunotherapy candidates, targeting autoimmune diseases (SDC-1801) and cancers (SDC-1802). Both molecules demonstrate high selectivity for TYK2 and JAK1 kinases, promising early safety data as well as compelling activity in relevant disease models. In addition, both programmes represent unique licensing opportunities for pharmaceutical partners as there are currently no marketed products with the selectivity profile of these molecules.
My favourite bit is ‘PROMISING EARLY SAFETY DATA’
Thinking we would know by now if something was up